Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Price to Sales (P/S)
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Illumina Inc., P/S, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).

1 US$

2 Data adjusted for splits and stock dividends.

3 Closing price as at the filing date of Illumina Inc. Annual Report.


Share Price
The share price exhibits significant growth over the observed period. Beginning at $12.79 in 2006, it showed a steady upward trajectory with some fluctuations, notably increasing to $69.40 in 2011, before experiencing a decline to $48.73 by 2013. Subsequently, a robust surge occurred, reaching a peak of $494.24 in 2021. This overall trend indicates strong market confidence and substantial value appreciation during these years.
Sales per Share
Sales per share consistently increased throughout the period, starting from $0.89 in 2006 to a peak of $24.10 in 2020. There was a slight decrease to $22.20 in 2021, which interrupts the otherwise upward growth pattern. The sustained increase over most years suggests steady revenue growth on a per-share basis, reflecting improving operational performance or increased sales volume.
Price-to-Sales (P/S) Ratio
The P/S ratio showed considerable volatility during the period. Initially, it was relatively high at 14.36 in 2006, then fluctuated downwards to a low of 5.26 in 2013. From 2013 onwards, it generally increased again, reaching 22.26 in 2021, the highest in the period. The variation in this ratio highlights changes in market valuation relative to sales, with the sharp rise in 2021 suggesting that the market may have assigned a premium valuation relative to the company's revenue at that time.

Comparison to Competitors

Illumina Inc., P/S, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Illumina Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2017-01-01), 10-K (reporting date: 2016-01-03), 10-K (reporting date: 2014-12-28), 10-K (reporting date: 2013-12-29), 10-K (reporting date: 2012-12-30), 10-K (reporting date: 2012-01-01), 10-K (reporting date: 2011-01-02), 10-K (reporting date: 2010-01-03), 10-K (reporting date: 2008-12-28), 10-K (reporting date: 2007-12-30), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2006-01-01).


Comparison to Industry (Health Care)